EVIDENCE-GOVERNED RESEARCH FUNNEL
The candidate layer is separate from the release portfolio. It compresses a broad discovery universe through quantitative, advanced-model, evidence, catalyst, and risk review so the strongest research questions receive deeper attention.
CANDIDATE DATE
Jul 10, 2026
FUNNEL ARCHITECTURE
Cheap quantitative screening comes first. Higher-cost evidence and qualitative review are reserved for a much smaller set.
2,399
Valid Securities
Discovery securities with valid current feature data.
2,000
Broad Research Universe
Liquidity and history governed universe.
200
Quantitative Screen
Fast cross-sectional technical screening.
50
Advanced Evaluation
Hardened model, uncertainty, risk and data quality.
30
Agentic Research
Evidence-governed qualitative assessment.
20
Research Candidates
Final monitored candidates, not portfolio weights.
FINAL RESEARCH SET
20
monitored candidates
PRIMARY EVIDENCE
7
35% of candidate set
RED-FLAG FREE
7
no governed flags
EXTERNAL CATALYSTS
0
currently verified
IN PLAIN ENGLISH
CANDIDATE INTELLIGENCE
Search or filter the governed stack. Expand a candidate to inspect the thesis, risk review, catalyst treatment, score layers, liquidity, and source types.
Applied Materials, Inc. - Common Stock
1.187
AGENTIC
90.5%
CONFIDENCE
12
EVIDENCE
LAST PRICE
$602.5
MEDIAN DOLLAR VOLUME
$3.8B
DRAWDOWN RESILIENCE
76.7%
MODEL UNCERTAINTY
0.00214
THESIS
AMAT ranks 5/50 in the advanced queue. The hardened model score is 0.01189 and the quantitative score is 1.150. The evidence-grounded fundamental assessment is 0.85; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.65, based on 20-day volatility 0.066, drawdown resilience 0.767, model uncertainty 0.00214, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.150
QUANT
0.01189
MODEL
0.847
FUNDAMENTAL
0.546
MACRO FIT
0.649
RISK
1.000
EVIDENCE
0.500
CATALYST
0.905
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
BlackBerry Limited Common Stock
0.819
AGENTIC
90.5%
CONFIDENCE
12
EVIDENCE
LAST PRICE
$10.97
MEDIAN DOLLAR VOLUME
$244.0M
DRAWDOWN RESILIENCE
63.0%
MODEL UNCERTAINTY
0.00150
THESIS
BB ranks 8/50 in the advanced queue. The hardened model score is 0.01223 and the quantitative score is 1.164. The evidence-grounded fundamental assessment is 0.71; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.58, based on 20-day volatility 0.065, drawdown resilience 0.630, model uncertainty 0.00150, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.164
QUANT
0.01223
MODEL
0.714
FUNDAMENTAL
0.475
MACRO FIT
0.577
RISK
1.000
EVIDENCE
0.500
CATALYST
0.905
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Entravision Communications Corporation Common Stock
0.798
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$11.76
MEDIAN DOLLAR VOLUME
$20.6M
DRAWDOWN RESILIENCE
76.5%
MODEL UNCERTAINTY
0.00167
THESIS
EVC ranks 2/50 in the advanced queue. The hardened model score is 0.01224 and the quantitative score is 1.395. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.70, based on 20-day volatility 0.052, drawdown resilience 0.765, model uncertainty 0.00167, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.395
QUANT
0.01224
MODEL
0.500
FUNDAMENTAL
0.641
MACRO FIT
0.702
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Oruka Therapeutics, Inc. - Common Stock
0.779
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$86.79
MEDIAN DOLLAR VOLUME
$88.1M
DRAWDOWN RESILIENCE
72.0%
MODEL UNCERTAINTY
0.00147
THESIS
ORKA ranks 1/50 in the advanced queue. The hardened model score is 0.01209 and the quantitative score is 1.900. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.66, based on 20-day volatility 0.053, drawdown resilience 0.720, model uncertainty 0.00147, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.900
QUANT
0.01209
MODEL
0.500
FUNDAMENTAL
0.581
MACRO FIT
0.659
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Advanced Micro Devices, Inc. - Common Stock
0.622
AGENTIC
90.5%
CONFIDENCE
11
EVIDENCE
LAST PRICE
$557.89
MEDIAN DOLLAR VOLUME
$15.0B
DRAWDOWN RESILIENCE
72.2%
MODEL UNCERTAINTY
0.00226
THESIS
AMD ranks 9/50 in the advanced queue. The hardened model score is 0.01114 and the quantitative score is 1.620. The evidence-grounded fundamental assessment is 0.52; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.64, based on 20-day volatility 0.051, drawdown resilience 0.722, model uncertainty 0.00226, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.620
QUANT
0.01114
MODEL
0.521
FUNDAMENTAL
0.559
MACRO FIT
0.641
RISK
1.000
EVIDENCE
0.500
CATALYST
0.905
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Palvella Therapeutics, Inc. - Common Stock
0.557
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$144.76
MEDIAN DOLLAR VOLUME
$27.6M
DRAWDOWN RESILIENCE
68.9%
MODEL UNCERTAINTY
0.00266
THESIS
PVLA ranks 4/50 in the advanced queue. The hardened model score is 0.01262 and the quantitative score is 1.846. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.59, based on 20-day volatility 0.050, drawdown resilience 0.689, model uncertainty 0.00266, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.846
QUANT
0.01262
MODEL
0.500
FUNDAMENTAL
0.588
MACRO FIT
0.588
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Anterix Inc. - Common Stock
0.551
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$100.96
MEDIAN DOLLAR VOLUME
$23.1M
DRAWDOWN RESILIENCE
74.6%
MODEL UNCERTAINTY
0.00318
THESIS
ATEX ranks 3/50 in the advanced queue. The hardened model score is 0.01320 and the quantitative score is 1.842. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.53, based on 20-day volatility 0.072, drawdown resilience 0.746, model uncertainty 0.00318, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.842
QUANT
0.01320
MODEL
0.500
FUNDAMENTAL
0.518
MACRO FIT
0.529
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Arista Networks, Inc. Common Stock
0.501
AGENTIC
90.5%
CONFIDENCE
12
EVIDENCE
LAST PRICE
$186.96
MEDIAN DOLLAR VOLUME
$1.4B
DRAWDOWN RESILIENCE
71.7%
MODEL UNCERTAINTY
0.00291
THESIS
ANET ranks 39/50 in the advanced queue. The hardened model score is 0.00888 and the quantitative score is 1.932. The evidence-grounded fundamental assessment is 0.90; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.71, based on 20-day volatility 0.042, drawdown resilience 0.717, model uncertainty 0.00291, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.932
QUANT
0.00888
MODEL
0.903
FUNDAMENTAL
0.673
MACRO FIT
0.715
RISK
1.000
EVIDENCE
0.500
CATALYST
0.905
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Twist Bioscience Corporation - Common Stock
0.388
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$90.64
MEDIAN DOLLAR VOLUME
$115.8M
DRAWDOWN RESILIENCE
62.8%
MODEL UNCERTAINTY
0.00154
THESIS
TWST ranks 7/50 in the advanced queue. The hardened model score is 0.01201 and the quantitative score is 1.649. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.61, based on 20-day volatility 0.046, drawdown resilience 0.628, model uncertainty 0.00154, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.649
QUANT
0.01201
MODEL
0.500
FUNDAMENTAL
0.596
MACRO FIT
0.609
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
10x Genomics, Inc. - Common Stock
0.333
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$42.73
MEDIAN DOLLAR VOLUME
$90.3M
DRAWDOWN RESILIENCE
72.0%
MODEL UNCERTAINTY
0.00336
THESIS
TXG ranks 6/50 in the advanced queue. The hardened model score is 0.01279 and the quantitative score is 2.502. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.50, based on 20-day volatility 0.053, drawdown resilience 0.720, model uncertainty 0.00336, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
2.502
QUANT
0.01279
MODEL
0.500
FUNDAMENTAL
0.527
MACRO FIT
0.497
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Wayfair Inc. Class A Common Stock
0.310
AGENTIC
90.5%
CONFIDENCE
11
EVIDENCE
LAST PRICE
$89.23
MEDIAN DOLLAR VOLUME
$244.9M
DRAWDOWN RESILIENCE
48.2%
MODEL UNCERTAINTY
0.00117
THESIS
W ranks 16/50 in the advanced queue. The hardened model score is 0.01190 and the quantitative score is 1.508. The evidence-grounded fundamental assessment is 0.52; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.49, based on 20-day volatility 0.049, drawdown resilience 0.482, model uncertainty 0.00117, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.508
QUANT
0.01190
MODEL
0.522
FUNDAMENTAL
0.455
MACRO FIT
0.488
RISK
1.000
EVIDENCE
0.500
CATALYST
0.905
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Kymera Therapeutics, Inc. - Common Stock
0.306
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$119.35
MEDIAN DOLLAR VOLUME
$47.8M
DRAWDOWN RESILIENCE
72.3%
MODEL UNCERTAINTY
0.00284
THESIS
KYMR ranks 10/50 in the advanced queue. The hardened model score is 0.01268 and the quantitative score is 2.300. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.56, based on 20-day volatility 0.050, drawdown resilience 0.723, model uncertainty 0.00284, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
2.300
QUANT
0.01268
MODEL
0.500
FUNDAMENTAL
0.588
MACRO FIT
0.557
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Precigen, Inc. - Common Stock
0.182
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$5.32
MEDIAN DOLLAR VOLUME
$17.6M
DRAWDOWN RESILIENCE
59.5%
MODEL UNCERTAINTY
0.00173
THESIS
PGEN ranks 13/50 in the advanced queue. The hardened model score is 0.01222 and the quantitative score is 1.509. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.52, based on 20-day volatility 0.057, drawdown resilience 0.595, model uncertainty 0.00173, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.509
QUANT
0.01222
MODEL
0.500
FUNDAMENTAL
0.463
MACRO FIT
0.522
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Enliven Therapeutics, Inc. - Common Stock
0.178
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$51.09
MEDIAN DOLLAR VOLUME
$36.6M
DRAWDOWN RESILIENCE
63.2%
MODEL UNCERTAINTY
0.00206
THESIS
ELVN ranks 17/50 in the advanced queue. The hardened model score is 0.01227 and the quantitative score is 2.004. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.57, based on 20-day volatility 0.047, drawdown resilience 0.632, model uncertainty 0.00206, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
2.004
QUANT
0.01227
MODEL
0.500
FUNDAMENTAL
0.588
MACRO FIT
0.573
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Solid Biosciences Inc. - Common Stock
0.162
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$10.42
MEDIAN DOLLAR VOLUME
$8.3M
DRAWDOWN RESILIENCE
55.6%
MODEL UNCERTAINTY
0.00314
THESIS
SLDB ranks 11/50 in the advanced queue. The hardened model score is 0.01298 and the quantitative score is 2.039. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.45, based on 20-day volatility 0.048, drawdown resilience 0.556, model uncertainty 0.00314, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
2.039
QUANT
0.01298
MODEL
0.500
FUNDAMENTAL
0.511
MACRO FIT
0.451
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Definium Therapeutics, Inc. - Common Shares
0.158
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$47.07
MEDIAN DOLLAR VOLUME
$48.1M
DRAWDOWN RESILIENCE
75.2%
MODEL UNCERTAINTY
0.00363
THESIS
DFTX ranks 12/50 in the advanced queue. The hardened model score is 0.01252 and the quantitative score is 2.148. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.48, based on 20-day volatility 0.118, drawdown resilience 0.752, model uncertainty 0.00363, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
2.148
QUANT
0.01252
MODEL
0.500
FUNDAMENTAL
0.456
MACRO FIT
0.484
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Moderna, Inc. - Common Stock
0.145
AGENTIC
90.5%
CONFIDENCE
11
EVIDENCE
LAST PRICE
$68.27
MEDIAN DOLLAR VOLUME
$333.3M
DRAWDOWN RESILIENCE
64.5%
MODEL UNCERTAINTY
0.00355
THESIS
MRNA ranks 14/50 in the advanced queue. The hardened model score is 0.01318 and the quantitative score is 1.785. The evidence-grounded fundamental assessment is 0.33; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.48, based on 20-day volatility 0.062, drawdown resilience 0.645, model uncertainty 0.00355, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.785
QUANT
0.01318
MODEL
0.329
FUNDAMENTAL
0.494
MACRO FIT
0.480
RISK
1.000
EVIDENCE
0.500
CATALYST
0.905
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
MillerKnoll, Inc. - Common Stock
0.109
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$20.16
MEDIAN DOLLAR VOLUME
$11.9M
DRAWDOWN RESILIENCE
62.2%
MODEL UNCERTAINTY
0.00230
THESIS
MLKN ranks 26/50 in the advanced queue. The hardened model score is 0.01101 and the quantitative score is 1.762. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.67, based on 20-day volatility 0.040, drawdown resilience 0.622, model uncertainty 0.00230, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.762
QUANT
0.01101
MODEL
0.500
FUNDAMENTAL
0.661
MACRO FIT
0.666
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Bio-Techne Corp - Common Stock
0.106
AGENTIC
62.0%
CONFIDENCE
4
EVIDENCE
LAST PRICE
$71.3
MEDIAN DOLLAR VOLUME
$148.2M
DRAWDOWN RESILIENCE
60.7%
MODEL UNCERTAINTY
0.00221
THESIS
TECH ranks 20/50 in the advanced queue. The hardened model score is 0.01127 and the quantitative score is 2.091. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.57, based on 20-day volatility 0.048, drawdown resilience 0.607, model uncertainty 0.00221, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
2.091
QUANT
0.01127
MODEL
0.500
FUNDAMENTAL
0.516
MACRO FIT
0.568
RISK
0.780
EVIDENCE
0.500
CATALYST
0.620
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
GE Vernova Inc. Common Stock
0.098
AGENTIC
90.5%
CONFIDENCE
12
EVIDENCE
LAST PRICE
$1.1K
MEDIAN DOLLAR VOLUME
$2.7B
DRAWDOWN RESILIENCE
75.4%
MODEL UNCERTAINTY
0.00230
THESIS
GEV ranks 40/50 in the advanced queue. The hardened model score is 0.01140 and the quantitative score is 1.441. The evidence-grounded fundamental assessment is 0.65; no missing fundamental value was replaced with current or future data.
RISK REVIEW
The risk assessment is 0.67, based on 20-day volatility 0.042, drawdown resilience 0.754, model uncertainty 0.00230, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.
CATALYST REVIEW
No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.
SCORE STACK
1.441
QUANT
0.01140
MODEL
0.650
FUNDAMENTAL
0.691
MACRO FIT
0.670
RISK
1.000
EVIDENCE
0.500
CATALYST
0.905
CONFIDENCE
GOVERNED SOURCE TYPES
Candidate rank is a research-prioritization output. It is not a portfolio weight, trade instruction, or suitability determination.
Primary supported
The packet includes accepted primary filing evidence. This raises evidence coverage; it does not make the investment conclusion automatically positive.
Internal only
The packet relies on internal model and market evidence. Confidence is capped rather than filled with unsupported assumptions.
Neutral catalyst
When no accepted external catalyst source exists, the catalyst assessment remains neutral instead of inferring a story from price action.
RESEARCH DISCLOSURE
What the numbers do—and do not—mean.